diff --git a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md index 45e141c32..597d0dd32 100644 --- a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md +++ b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md @@ -2,7 +2,7 @@ type: claim domain: health description: "92% of US health systems deploying AI scribes by March 2025 — a 2-3 year adoption curve vs 15 years for EHRs — because documentation is the one clinical workflow where AI improvement is immediately measurable, carries minimal patient risk, and delivers revenue capture gains" -confidence: proven +confidence: likely source: "Bessemer Venture Partners, State of Health AI 2026 (bvp.com/atlas/state-of-health-ai-2026)" created: 2026-03-07 --- @@ -51,16 +51,11 @@ WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural fac ### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-18* +*Source: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption | Added: 2026-03-18* Epic's AI Charting launch (Feb 2026) threatens to commoditize the ambient documentation beachhead that standalone AI companies used to establish clinical trust. Epic's 42% acute hospital market share and native EHR integration create 'good enough' dynamics where technical superiority matters less than bundled convenience. Early pilots show Epic comparable on simple notes but behind on complex specialties, suggesting the high-adoption documentation use case is splitting into commodity (Epic-captured) and premium (specialty-focused) segments. This challenges the interpretation that scribe adoption = sustainable moat—the beachhead may be rapidly commoditized by platform incumbents. -### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-19* - -Epic's February 2026 AI Charting launch threatens to commoditize the documentation beachhead. While AI scribes achieved 92% provider adoption, Epic's native integration advantage (full patient history access, single-vendor IT preference, add-on pricing vs. millions in standalone contracts) means the 'easy adoption' use case may not translate to sustainable competitive moats. Abridge CEO Shiv Rao is repositioning the company as 'more than an AI scribe' by pursuing prior authorization and clinical decision support, suggesting the documentation-only market is now contested. The high adoption rate may have been a function of being first to an undefended use case rather than a durable advantage. - --- Relevant Notes: diff --git a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md index 2d87913d0..0f59c5330 100644 --- a/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md +++ b/domains/health/AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md @@ -40,13 +40,13 @@ BVP reports AI-native healthcare companies achieve $500K-$1M+ ARR per FTE with 7 ### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-18* +*Source: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption | Added: 2026-03-18* Abridge's productivity premium may not survive platform commoditization. Despite being KLAS #1 ambient scribe with 150+ health system deployments, Epic's native AI Charting threatens Abridge's core documentation revenue through integration advantages and 'good enough' quality at lower switching costs. Abridge is repositioning toward clinical decision support and prior authorization—higher-value use cases Epic hasn't matched—suggesting the productivity premium only holds when the AI company can stay ahead of platform commoditization cycles. ### Additional Evidence (challenge) -*Source: [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] | Added: 2026-03-19* +*Source: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption | Added: 2026-03-19* Epic's platform commoditization of AI scribes suggests the productivity premium may not survive when incumbents add 'good enough' AI to existing workflows. Abridge's 150+ health system deployments and best-in-class accuracy face pressure from Epic's native integration, which doesn't require matching quality—just being sufficient for most documentation use cases. If platform incumbents can capture high-volume segments with lower-quality but better-integrated AI, the revenue productivity advantage may only persist in high-complexity niches where integration advantages don't overcome the quality gap. diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 3c392007c..10e716e0e 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -115,15 +115,15 @@ International generic competition beginning January 2026 (Canada patent expiry, ### Additional Evidence (challenge) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* +*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy. ### Additional Evidence (challenge) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* +*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* -If GLP-1 + exercise combination creates durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone) that persists after discontinuation, the chronic use economic model may be unnecessarily pessimistic. Value could accrue from shorter medication courses paired with intensive behavioral support, reducing long-term pharmaceutical spend while maintaining clinical benefits. +Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself. --- @@ -137,6 +137,11 @@ Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale. +### Additional Evidence (challenge) +*Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20* + +India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033. + ### Additional Evidence (challenge) *Source: 2026-03-22-health-canada-rejects-dr-reddys-semaglutide | Added: 2026-03-22* diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index a9b681e52..0b1cfc124 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -19,13 +19,13 @@ The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveragin ### Additional Evidence (extend) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-18* OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from 8.5M in 2025, representing 2,000%+ YoY growth), valuation increased from $3.5B to $12B in months, reached 1M consultations in a single day (March 10, 2026 milestone), used across 10,000+ hospitals. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight/explainability—trust barriers persist even among heavy users. ### Additional Evidence (extend) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-19* OpenEvidence reached 20M clinical consultations/month by January 2026 (up from 8.5M in 2025, representing 2,000%+ YoY growth). On March 10, 2026, OpenEvidence became the first AI system to reach 1M clinical consultations in a single day. The platform is now used across 10,000+ hospitals and medical centers nationwide. Valuation tripled from $3.5B to $12B in under 12 months, with a $250M Series D led by Thrive Capital and DST Global in January 2026. diff --git a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md index 522304e92..cc62ba37c 100644 --- a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md +++ b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md @@ -43,15 +43,15 @@ Community health worker programs demonstrate the same payment boundary stall: on ### Additional Evidence (challenge) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-18* +*Source: 2025-01-01-produce-prescriptions-diabetes-care-critique | Added: 2026-03-18* The Diabetes Care perspective challenges the 'strong ROI' claim for SDOH interventions by questioning whether produce prescriptions—a specific SDOH intervention—actually produce clinical outcomes. The observational evidence showing improvements may reflect methodological artifacts (self-selection, regression to mean) rather than true causal effects. This suggests the ROI evidence for SDOH interventions may be weaker than claimed, particularly for single-factor interventions like food provision. ### Additional Evidence (challenge) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-19* +*Source: 2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026 | Added: 2026-03-20* -The ADA's Diabetes Care journal questions whether produce prescriptions—a specific SDOH intervention type—generate clinical benefit despite improving food security metrics. Observational studies show diet quality improvements but lack controlled evidence for HbA1c reduction. Programs enrolling patients with very poor baseline control (HbA1c >9%) show improvements that may reflect regression to the mean rather than intervention effect. The clinical diabetes community is signaling that 'food as medicine' framing has outrun the evidence base for this intervention category. +The RSC's second reconciliation bill proposes site-neutral payments that would eliminate the enhanced FQHC reimbursement rates (~$300/visit vs ~$100/visit) that fund CHW programs. Combined with OBBBA's Medicaid cuts, this creates a two-vector attack on the institutional infrastructure that hosts most CHW programs. The challenge is not just documentation and operational infrastructure—the payment foundation itself is under legislative threat. Even if Z-code documentation improved and operational infrastructure was built, the revenue model that makes CHW programs economically viable within FQHCs would be eliminated by site-neutral payments. --- diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index a59269ef9..192f277ca 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -97,7 +97,7 @@ GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacol ### Additional Evidence (extend) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-19* +*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-19* Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise reduces regain to 3.5 kg. This suggests the low persistence rates may be economically rational from a patient perspective if medication alone provides no durable benefit—patients who discontinue without establishing exercise habits return to baseline regardless of medication duration. @@ -105,7 +105,7 @@ Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than pla ### Additional Evidence (extend) *Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* -Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than placebo (7.6 kg) after discontinuation, while combination with exercise (3.5 kg regain) maintains 60% more weight loss. This suggests the adherence paradox may be misframed—the economic value may not require chronic medication use if behavioral interventions create durable change that outlasts pharmacotherapy. +Aon data shows benefits scale dramatically with adherence: for diabetes patients, medical cost growth is 6 percentage points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months overall, but 7 points lower with consistent use. Adherent users (80%+) show 47% fewer MACE hospitalizations for women and 26% for men. This confirms that adherence is the binding variable—the 80%+ adherent cohort shows the strongest effects across all outcomes, making low persistence rates even more economically damaging. --- diff --git a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md index f829c9673..a531c2268 100644 --- a/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md +++ b/domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md @@ -27,16 +27,11 @@ Abridge raised $300M Series E at $5B valuation and Ambiance raised $243M Series ### Additional Evidence (confirm) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-18* OpenEvidence valuation trajectory demonstrates winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with $250M Series D led by Thrive Capital and DST Global. This 3.4x valuation increase in months while 35% of healthcare AI deals are flat/down rounds confirms capital concentration in category leaders. -### Additional Evidence (confirm) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* - -OpenEvidence valuation trajectory demonstrates extreme winner-take-most dynamics: $3.5B → $6B → $12B in under 12 months, with a $250M Series D in January 2026. This represents the fastest capital absorption in clinical AI history, with valuation tripling while the broader market shows 35% of deals at flat or down rounds. OpenEvidence is capturing category-defining capital velocity in clinical reasoning AI, separate from the ambient scribe market. - --- ### Additional Evidence (confirm) diff --git a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md index 0e61caa9b..944a01cc4 100644 --- a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md +++ b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md @@ -19,13 +19,13 @@ The implication for AI deployment strategy: the highest-value clinical AI applic ### Additional Evidence (challenge) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-18* OpenEvidence achieved 100% USMLE score (first AI in history) and is now deployed at 20M consultations/month across 40%+ of US physicians, creating the first large-scale empirical test of whether benchmark performance translates to population health outcomes. The absence of published outcomes data at this deployment scale represents a critical evidence gap—if benchmark performance doesn't translate to clinical impact, we should see evidence of that at 20M monthly consultations. ### Additional Evidence (challenge) -*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-19* +*Source: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation | Added: 2026-03-19* OpenEvidence became the first AI in history to score 100% on all parts of the USMLE, exceeding any human score on the most challenging medical licensing exam. This creates an empirical test case: OpenEvidence is now deployed at scale (20M consultations/month, 40%+ of US physicians daily) with perfect benchmark performance, yet no peer-reviewed outcomes data demonstrates whether this translates to improved patient outcomes. The absence of outcomes data at this scale represents a critical gap in validating whether benchmark performance predicts clinical impact. diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index 14bc59c0f..bce7aa65f 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -55,7 +55,7 @@ While social determinants predict health outcomes in observational studies, RCT ### Additional Evidence (extend) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-18* +*Source: 2025-01-01-produce-prescriptions-diabetes-care-critique | Added: 2026-03-18* The Diabetes Care perspective provides a specific mechanism example: produce prescription programs may improve food security (a social determinant) without improving clinical outcomes (HbA1c, diabetes control) because the causal pathway from social disadvantage to disease is not reversible through single-factor interventions. This demonstrates the 10-20% medical care contribution in practice—addressing one SDOH factor (food access) doesn't overcome the compound effects of poverty, stress, and social disadvantage. @@ -67,7 +67,7 @@ Amodei's complementary factors framework explicitly identifies 'human constraint ### Additional Evidence (extend) -*Source: [[2025-01-01-produce-prescriptions-diabetes-care-critique]] | Added: 2026-03-19* +*Source: 2025-01-01-produce-prescriptions-diabetes-care-critique | Added: 2026-03-19* The produce prescription evidence gap illustrates the mechanism: knowing that social factors (food quality) drive health outcomes doesn't automatically mean that interventions targeting those factors (food vouchers) improve health. Food insecurity may be a proxy for poverty/stress/disadvantage rather than a direct causal factor. The ADA perspective shows that even when the correlation between social factors and health is proven, the causal pathway for interventions remains uncertain—food provision may improve food security without improving clinical outcomes if the underlying social determinants remain unaddressed. diff --git a/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md b/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md index ce955afd1..7454bb4d0 100644 --- a/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md +++ b/inbox/archive/health/2025-01-01-produce-prescriptions-diabetes-care-critique.md @@ -14,10 +14,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -79,8 +75,3 @@ EXTRACTION HINT: The distinction between "food matters for health" (proven) and - The American Diabetes Association's journal is questioning the evidence standard for produce prescriptions -## Key Facts -- Diabetes Care published 'Food Is Medicine, but Are Produce Prescriptions?' perspective in 2023 -- Observational produce prescription evaluations include multisite 9-program studies and Recipe4Health -- Programs showing HbA1c improvements typically enroll patients with baseline HbA1c >9% -- The American Diabetes Association is the publisher of Diabetes Care journal diff --git a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md index 0bd1728dc..2c958d9d3 100644 --- a/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md +++ b/inbox/archive/health/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md @@ -14,10 +14,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -78,18 +74,6 @@ WHY ARCHIVED: Significant scale update — the existing claim understates 2026 m EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim -## Key Facts -- OpenEvidence reached 8.5M clinical consultations/month in 2025 -- OpenEvidence reached 20M clinical consultations/month by January 2026 -- OpenEvidence valuation: $3.5B → $6B → $12B in under 12 months -- OpenEvidence Series D: $250M led by Thrive Capital and DST Global (January 2026) -- OpenEvidence first AI to score 100% on USMLE (all parts) -- OpenEvidence used across 10,000+ hospitals and medical centers -- March 10, 2026: OpenEvidence reached 1M consultations in one day -- 44% of physicians concerned about OpenEvidence accuracy/misinformation risk -- 19% of physicians concerned about lack of physician oversight/explainability - - ## Key Facts - OpenEvidence reached 8.5M clinical consultations/month in 2025 - OpenEvidence reached 20M clinical consultations/month by January 2026 diff --git a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md index 6c52d13de..9f4318347 100644 --- a/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md +++ b/inbox/archive/health/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption.md @@ -15,10 +15,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md", "AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md", "AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -85,11 +81,3 @@ EXTRACTION HINT: The "good enough" dynamic is the key claim — extract that as - Standalone scribe contracts can reach millions annually for health systems -## Key Facts -- Epic Systems controls 42% of acute hospital EHR market share as of Feb 2026 -- Epic covers 55% of US hospital beds -- Abridge won top ambient scribe slot in 2025 KLAS annual report -- Abridge has 150+ health system deployments as of Feb 2026 -- Ambient scribe market estimated at $2B -- Standalone AI scribe contracts can reach millions annually for health systems -- Early Epic AI Charting pilots show comparable performance on simple note types, significantly behind on complex specialties diff --git a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md index d068c7334..97aad2958 100644 --- a/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md +++ b/inbox/archive/health/2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach.md @@ -14,14 +14,6 @@ processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] -extraction_model: "anthropic/claude-sonnet-4.5" -processed_by: vida -processed_date: 2026-03-19 -enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] -extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -94,24 +86,7 @@ EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison - Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass - Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced - Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions -- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) -- BALANCE model includes lifestyle support component but specific exercise programming details not specified in source - - -## Key Facts -- WHO December 2025 guidelines specifically recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits' -- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass -- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced -- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of weight loss interventions - At week 52 all intervention groups regained weight after stopping; by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg - Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data, not FDA-approved for this indication) - ADA notes new therapies claiming 'enhanced quality of weight loss by improving muscle preservation' but no FDA-approved compounds with proven muscle preservation yet - - -## Key Facts -- Meta-analysis of 22 RCTs with 2,258 participants found approximately 25% of GLP-1 weight loss is lean mass -- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced -- Up to 50% of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% independent of interventions -- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy' -- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary, not FDA-approved) -- Weight regain by week 104: placebo +7.6 kg, liraglutide only +8.7 kg, exercise only +5.4 kg, combination +3.5 kg +- BALANCE model includes lifestyle support component but specific exercise programming details not specified in source